SANTA MONICA, Calif.–(BUSINESS WIRE)–Mar. 5, 2021– Kite, a Gilead Company (Nasdaq: GILD),
Read moreU.S. FDA Approves Yescarta for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
Home »
Novel treatment avenue for resistant cancers: Removing SORLA protein from drug-resistant HER2-positive cancer cell lines
SORLA is a protein trafficking receptor that has been mainly
Read moreState gun laws may help curb violence across state lines
Columbia University Mailman School of Public Health researchers find that
Read more